TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
Portfolio Pulse from
TC BioPharm (NASDAQ: TCBP) has successfully completed dosing of Cohort A in its ACHIEVE Phase 2B clinical trial, showing favorable safety and efficacy for its TCB008 therapy in patients with relapse or refractory AML.
February 13, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm has successfully completed Cohort A in its ACHIEVE Phase 2B trial, showing positive safety and efficacy for TCB008 in AML patients, which could boost investor confidence.
The successful completion of Cohort A with favorable safety and efficacy results is a positive development for TC BioPharm, likely to increase investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100